Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
148.43
-0.12 (-0.08%)
At close: Feb 11, 2026, 4:00 PM EST
147.17
-1.26 (-0.85%)
After-hours: Feb 11, 2026, 7:44 PM EST
Insmed Employees
Insmed had 1,271 employees as of December 31, 2024. The number of employees increased by 359 or 39.36% compared to the previous year.
Employees
1,271
Change (1Y)
359
Growth (1Y)
39.36%
Revenue / Employee
$351,709
Profits / Employee
-$931,423
Market Cap
31.66B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 1,271 | 359 | 39.36% |
| Dec 31, 2023 | 912 | 176 | 23.91% |
| Dec 31, 2022 | 736 | 123 | 20.07% |
| Dec 31, 2021 | 613 | 92 | 17.66% |
| Dec 31, 2020 | 521 | 86 | 19.77% |
| Dec 31, 2019 | 435 | 62 | 16.62% |
| Dec 31, 2018 | 373 | 159 | 74.30% |
| Dec 31, 2017 | 214 | 53 | 32.92% |
| Dec 31, 2016 | 161 | 36 | 28.80% |
| Dec 31, 2015 | 125 | 36 | 40.45% |
| Dec 31, 2014 | 89 | 28 | 45.90% |
| Dec 31, 2013 | 61 | 20 | 48.78% |
| Dec 31, 2012 | 41 | -1 | -2.38% |
| Dec 31, 2011 | 42 | 2 | 5.00% |
| Dec 31, 2010 | 40 | 25 | 166.67% |
| Dec 31, 2009 | 15 | -82 | -84.54% |
| Dec 31, 2008 | 97 | 3 | 3.19% |
| Dec 31, 2007 | 94 | -63 | -40.13% |
| Dec 31, 2006 | 157 | 72 | 84.71% |
| Dec 31, 2005 | 85 | 30 | 54.55% |
| Dec 31, 2004 | 55 | 35 | 175.00% |
| Dec 31, 2003 | 20 | -3 | -13.04% |
| Dec 31, 2002 | 23 | -37 | -61.67% |
| Dec 31, 2001 | 60 | 20 | 50.00% |
| Dec 31, 2000 | 40 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 11,000 |
| BioNTech SE | 6,772 |
| Moderna | 5,800 |
| Genmab | 2,681 |
| Incyte | 2,617 |
| Alnylam Pharmaceuticals | 2,230 |
| argenx SE | 1,599 |
| Revolution Medicines | 809 |
INSM News
- 6 days ago - Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026 - PRNewsWire
- 9 days ago - Insmed: A Brensocatib Pipeline Setback Is Masking A Dupixent-Like Launch - Seeking Alpha
- 13 days ago - Artisan Global Opportunities Fund Q4 2025 Portfolio Update - Seeking Alpha
- 14 days ago - Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress - PRNewsWire
- 19 days ago - Artisan Small Cap Fund Q4 2025 Portfolio Activity - Seeking Alpha
- 23 days ago - Artisan Mid Cap Fund Q4 2025 Performance Discussion And Portfolio Activity - Seeking Alpha
- 4 weeks ago - Insmed Incorporated (INSM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Insmed Maps Aggressive 2026 As Newly Approved Lung Disease Drug Gains Traction, Pipeline Advances - Benzinga